Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD

NCT04543812 is registered in ClinicalTrials.gov with Panion & BF Biotech Inc. as lead sponsor.

NCT NCT04543812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD
Lead sponsor
Panion & BF Biotech Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 14, 2020
Completion date
December 16, 2022
Enrollment
141 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease